Clearside Biomedical Pursues Strategic Sale Through Chapter 11 Process

martes, 25 de noviembre de 2025, 4:09 pm ET1 min de lectura
CLSD--

• Clearside Biomedical files for Chapter 11 bankruptcy • Aims to maximize stakeholder value through strategic sale • Validates SCS Microinjector delivery platform • Anchored by commercial product and five licensing collaborations • CLS-AX TKI program includes Phase 3-ready asset for Wet AMD • Path for Phase 2b/3 trial in diabetic retinopathy • IND-ready programs targeting geographic atrophy and diabetic macula edema

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios